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Goodpasture syndrome
fied as the a3(IV) NC1 domain [12]. The autoantibodiesGoodpasture syndrome (GP) is an autoimmune dis-
from all patients reacted with the a3NC1 domain, withease that is frequently characterized by rapidly progres-
85% of the patients binding exclusively to thesive glomerulonephritis, occasional pulmonary hemor-
a3(IV)NC1. Some patients revealed additional reactivityrhage and autoantibodies to the glomerular and alveolar
to the a1(IV)NC1 and a4(IV)NC1, 15% and 4%, respec-basement membranes [1–4]. The primary target for cir-
tively [12].culating and tissue bound antibodies, and T-cells, has
Evidence of genetic susceptibility to human anti-GBMbeen identified as the NC1 domain of a3 chain of type
disease and Goodpasture syndrome was initially limitedIV collagen [5, 6]. Type IV collagen is the major protein
to a study of twins and an association with MHC haplo-constituent of mammalian basement membranes. The
types mapping to the class II HLA-D region [13]. Subse-building unit of type IV collagen (protomer) is composed
of three a-chains, and is characterized by three structural quent studies further illustrated that autoimmunity to the
domains: 7 S at the amino terminus; a long triple helical NC1 domain of a3 chain of type IV collagen is strongly
domain in the middle region; and an NC1 domain at associated with HLA-DR15 in Goodpasture syndrome
the carboxyl terminus [5]. The a3 chain is one of six [14, 15]. MHC Class II molecules are believed to in-
genetically distinct polypeptides that can participate to fluence immune responses by binding selectively to
form protomers of type IV collagen [5]. Two type IV a3(IV)NC1-derived peptides for recognition by T-cells
collagen protomers can come together via their carboxyl [16]. Animal models over the last few decades have at-
NC1 domains to form a hexameric NC1 structure. Thus tempted to approximate human Goodpasture syndrome,
far, the epitope(s) for the Goodpasture autoantibodies and two such models have been established in rats and
have been localized to the a3 NC1 domain [5]. These mice [17–19]. In both the models certain genetic suscepti-
epitope(s) appear to be sequestered within the NC1 hex- bilities for the inflammation associated with Goodpas-
amer structure, but in the presence of SDS, urea or ture syndrome were observed [17–19]. Recent studies in
guanidine become exposed to autoantibody binding, as mice with anti-GBM disease suggest a pivotal role for
assessed by in vitro experiments [5, 7, 8]. In the in vivo cytokines such as interleukin (IL)-6, IL-4, IL-12 and
setting it is speculated that initiating events such as infec- transforming growth factor-b (TGF-b) in the expression
tion, exposure to toxins, renal injury, ischemia and vari- of disease [19]. Additionally, in mice it was established
ous types of neoplasia could expose cryptic epitopes by that crescentic glomerulonephritis and lung hemorrhage
altering the structure of the glomerular basement mem- associated with anti-a3(IV) collagen antibodies is re-
brane (GBM). Moreover, the epitope(s) within the NC1 stricted to MHC haplotypes H-2s, b, d that express addi-
domain is speculated to be conformational and depen- tional IL-12, g-INF and IgG2a/Th1-like responses that
dent on proper disulfide linkage [5]. map to the Ab/Aa region of H-2s, a region that corre-
The identity of the a3 chain as the Goodpasture au- sponds to HLA-DR/DQ in humans [19]. These studies
toantigen was established through biochemical, immuno- suggest that humoral response to a3(IV)NC1 may not
logical and molecular studies. These involved the use of be sufficient, and for full blown inflammation associated
bacterial collagenase to digest GBM preparations and with Goodpasture syndrome, effector mechanisms asso-
the identification of a 28 kDa protein, which was subse- ciated with cell mediated immunity along with B-cell
quently identified as the NC1 domain of a3(IV) chain [9]. responses towards a3(IV)NC1 may be required.
These earlier biochemical experiments were confirmed Two reports in this issue of Kidney International fur-
later by the molecular cloning of the antigen and genera- ther solidify the significance of a3(IV)NC1 in the patho-
tion of human recombinant a3(IV)NC1 domain in vari- genesis and disease progression of Goodpasture syn-
ous in vitro expression systems [10, 11]. In one such drome [20, 21]. In the article by Leinonen et al, the full
subsequent study, the principal target for circulating au- length (1640 amino acids) human a3 chain [r-a3(IV)]
toantibodies from 58 Goodpasture patients was identi- was assembled by PCR and the cDNA construct was
stably transfected into human embryonic kidney 293 cells
[20]. The full length chain was expressed as a fusionKey words: Goodpasture, GBM, kidney, a3(IV) collagen, autoim-
mune, epitope. protein with N-terminal flag sequence, which enabled
single step affinity purification. The r-a3(IV) chain ap- 1999 by the International Society of Nephrology
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peared as a double band with a molecular size of around parts of a3(IV)NC1 were replaced by a1(IV)NC1. In
total, eight constructs were generated and results indi-200 kDa as observed by SDS-PAGE under non-reducing
conditions and after reduction of disulfide bonds as a cated that the predominant binding site for all the 77
Goodpasture autoantibodies tested was located in thesingle band with molecular size of 250 kDa [20]. The
r-a3(IV) chain under non-reducing conditions bound to amino terminal third of the a3(IV)NC1 domain [21].
More than 50 patients showed additional reactivitiesfive different Goodpasture autoantibodies, and this bind-
ing was localized to the NC1 domain by collagenase to the middle and C-terminal region of the a3(IV)NC1.
The authors suggest that only antibodies with defineddigestion of this recombinant molecule and not to the
triple helical portion or the 7 S region of the molecule. specificity for the amino terminal region of a3(IV)NC1
correlated with progression to end-stage renal disease.An important point to note here is that type IV collagen
isoforms including the a3 chain have not been purified No such correlation was found with ELISA reactivities
against the middle or C-terminus part of the a3(IV)NC1.in their intact forms due to their insoluble nature, and
thus all earlier studies dealing with the identification Generally, patients with normal kidney function after
six months from initial presentation revealed several re-of Goodpasture autoantigen used collagenase solubil-
ized GBM [9]. Thus, the question as to whether there activities to the a3(IV)NC1 domain with no one favored
binding site [21]. In contrast to the progression of kidneyare any other epitopes on the a3 chain for Goodpas-
ture autoantibodies remained unanswered until this re- disease in Goodpasture syndrome, no such fine correla-
tion was observed between patients with and withoutport [20].
Rotary shadow electron microscopy analysis of the lung involvement. Collectively these results provide a
basis for monitoring prognostic indicators in the serumr-a3(IV) exhibited interesting intermolecular associa-
tions [20]. NC1 domain dimerization and other aggrega- of Goodpasture patients for recovery of renal function.
This is an important study, as defined epitope specificitytions were observed between two or more r-a3(IV) mol-
ecules, and rare rod-like extensions to globular domains analysis may provide the basis for development of
better therapeutic regimens for this sometimes fatal dis-were noticed [20]. The interesting feature of these rod-
like structures is that they do not form an expected triple ease [21].
Goodpasture syndrome is emerging as a prototypehelical collagenous structure, as noted by their suscepti-
bility to pepsin digestion (pepsin is known not to digest for all the autoimmune disorders at the biochemical,
molecular and immunological levels. This disease is or-collagenous triple helical structures). These observations
and a potential lack of sufficient hydroxylation of proline gan specific and a single pathogenic antigen [a3(IV)NC1]
has been identified. Both B-cells and T-cells elicit patho-and lysine residues led the authors to conclude that the
r-a3(IV) is not capable of forming homotrimers in this genic responses to the same antigen. Exposure to this
antigen induces a disease almost identical to Goodpas-expression system [20], although alternate explanations
might include the potential lack of certain chaperones ture syndrome in several different animal species, thus
providing highly representative disease models for thisrequired for type IV collagen folding in the embryonic
kidney 293 cells. Nevertheless, the observation that the human syndrome. The articles in the current issue of
Kidney International further solidify the importance ofrecombinant molecule did not spontaneously undergo
assembly into a triple helical homotrimeric molecule sug- a3(IV)NC1 in the pathogenesis of human Goodpasture
syndrome [20, 21].gests that co-assembly with either the a4(IV) and/or the
a5(IV) chain may be required for triple helix formation, Lastly, Goodpasture syndrome is a true example of
how orphan diseases can be a window to new biology.as previously speculated by several investigators [5, 22].
Overall this manuscript makes three important ob- From the time when several investigators demonstrated
linear binding of endogenous IgG to the GBM of patientsservations [20]: (1) the unequivocal determination of
a3(IV)NC1 domain as the region for Goodpasture auto- with Goodpasture syndrome, experiments have been
carried out to identify the target for these autoantibodies.antibody binding; (2) the capacity to generate full length
a-chain of type IV collagen in 293 cells; and (3) a sugges- In the 1980s, these investigations led to the discovery
of type IV collagen as target antigen and subsequenttion that protomer formation involving a3 chain may
require a4 and a5 chains. research to identify the epitope for these autoantibodies
within type IV collagen led to the discovery of a newIn the article by Hellmark et al in this issue of Kidney
International, an attempt was made for the first time to protein, the a3(IV) chain. This identification was based
on its homology and biochemical association with a1(IV)correlate the disease progression and clinical outcome
of Goodpasture syndrome with defined specificity and and a2(IV) collagens [9]. These studies formed the basis
for the discovery of several other matrix molecules, in-titer of patient antibodies to epitopes within the a3NC1
domain [21]. For mapping of autoantibody binding cluding the a5 chain of type IV collagen (the Alport
gene). Additionally, search for the Goodpasture antigento a3(IV)NC1 domain, chimeric molecules between
a3(IV)NC1 and a1(IV)NC1 were generated in which has led to a better understanding of the unique composi-
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